La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Rezolute Croissance future

Future contrôle des critères 2/6

Rezolute devrait augmenter ses bénéfices et ses revenus de 36.5% et de 61.7% par an respectivement, tandis que le BPA devrait croître de croître de 33.2% par an.

Informations clés

46.1%

Taux de croissance des bénéfices

41.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.0%
Taux de croissance des recettes	60.7%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	27 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:RZLT - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2027	70	-43	-35	-87	7
6/30/2026	23	-73	-56	-68	8
6/30/2025	16	-57	-66	-61	10
6/30/2024	N/A	-63	-57	-50	10
3/31/2024	N/A	-58	-50	-50	N/A
12/31/2023	N/A	-57	-53	-53	N/A
9/30/2023	N/A	-56	-48	-47	N/A
6/30/2023	N/A	-52	-45	-44	N/A
3/31/2023	N/A	-48	-45	-45	N/A
12/31/2022	N/A	-44	-41	-41	N/A
9/30/2022	N/A	-43	-41	-41	N/A
6/30/2022	N/A	-41	-40	-40	N/A
3/31/2022	N/A	-38	-33	-33	N/A
12/31/2021	N/A	-31	-24	-24	N/A
9/30/2021	N/A	-25	-23	-23	N/A
6/30/2021	N/A	-21	-20	-20	N/A
3/31/2021	N/A	-18	-19	-19	N/A
12/31/2020	N/A	-19	-20	-20	N/A
9/30/2020	N/A	-19	-19	-19	N/A
6/30/2020	N/A	-20	-24	-24	N/A
3/31/2020	N/A	-20	-24	-24	N/A
12/31/2019	N/A	-37	-27	-27	N/A
9/30/2019	N/A	-34	-23	-23	N/A
6/30/2019	N/A	-33	-15	-15	N/A
3/31/2019	N/A	-42	-15	-15	N/A
12/31/2018	N/A	-25	-9	-9	N/A
9/30/2018	N/A	-27	-11	-11	N/A
6/30/2018	N/A	-30	-14	-14	N/A
3/31/2018	N/A	-24	-14	-14	N/A
12/31/2017	N/A	-27	N/A	-15	N/A
9/30/2017	N/A	-27	N/A	-15	N/A
6/30/2017	N/A	-24	N/A	-13	N/A
3/31/2017	N/A	-27	N/A	-13	N/A
12/31/2016	N/A	-22	N/A	-12	N/A
9/30/2016	N/A	-21	N/A	-11	N/A
6/30/2016	N/A	-21	N/A	-10	N/A
3/31/2016	N/A	-14	N/A	-9	N/A
12/31/2015	N/A	-14	N/A	-9	N/A
9/30/2015	N/A	-12	N/A	-8	N/A
6/30/2015	N/A	-11	N/A	-7	N/A
3/31/2015	N/A	-10	N/A	-7	N/A
12/31/2014	N/A	-12	N/A	-6	N/A
9/30/2014	N/A	-11	N/A	-5	N/A
6/30/2014	N/A	-10	N/A	-3	N/A
3/31/2014	N/A	-9	N/A	-1	N/A
12/31/2013	N/A	-8	N/A	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: RZLT devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: RZLT devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: RZLT devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de RZLT ( 61.7% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de RZLT ( 61.7% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de RZLT devrait être élevé dans 3 ans

Rezolute Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 9.4% to US$10.57

Price target increased by 9.0% to US$8.50

Price target decreased by 30% to US$7.80

Price target decreased by 7.9% to US$11.60

Price target decreased to US$12.60

Price target decreased to US$19.20

Recent updates

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98

Rezolute, Inc. Announces Phase 2B Study of RZ358 Continues to Enroll Congenital Hyperinsulinism (HI) Patients Worldwide

Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

New 90-day low: US$12.94

Rezolute, Inc. Announces Resignation of Jung-Hee Lim as a Member of the Board of Directors, Audit Committee and Compensation Committee

Price target raised to US$31.50

Rezolute, Inc. Announces CFO Changes

Rezolute, Inc. announced that it expects to receive $40.92 million in funding from BVF Partners LP, Citadel Advisors LLC, and other investors

Rezolute, Inc. announced delayed annual 10-K filing

Rezolute Announces Publication of Rz402 Data in Diabetic Macular Edema (Dme) in Investigative Ophthalmology & Visual Science

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance